We have created an interactive dashboard ~ What Is The Q3 Outlook For Pfizer ~ on the company’s expected performance in 2018. Expect Oncology To Continue To See Strong GrowthWe expect the company’s Oncology segment to continue to drive top line growth for Pfizer in the near term, primarily led by its breast cancer drug – Ibrance. The drug sales were over $1 billion in Q2 2018, and we forecast it to be around $4 billion for the full year. In fact, we expect biosimilars to be one of the key drivers for Pfizer’s future growth. This should bode well for the drug’s sales growth in the coming quarters.

Source: Forbes October 29, 2018 16:52 UTC